Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774218 | 0.94 | USP30 (0.43) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL18838278 | 0.94 | USP30 (0.43) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL17761048 | 0.88 | MAPK1 (0.42) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL3658167 | 0.88 | MAPK1 (0.42) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL16914261 | 0.88 | USP30 (0.44) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL18087311 | 0.87 | USP2 (0.45) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL5895323 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2USP30MAPTKDM4E | |
| SCHEMBL24089120 | 0.85 | USP2 (0.50) | ESR2USP2SMN1; SMN2USP30MAPT | |
| SCHEMBL8775525 | 0.85 | NR1H2 (0.48) | ESR2NR1H2USP2SMN1; SMN2USP30 | |
| SCHEMBL5304158 | 0.84 | MAPK1 (0.42) | ESR2NR1H2USP2SMN1; SMN2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025245003-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-21 | — | — | US | disclosed |
| EP-2307387-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082294-A1 | NOVEL BICYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-07 | — | — | US | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010012619-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | HCRTR2, HCRTR1, CRHR2 | ESR2 345/4885NR1H2 10/4885USP2 2133/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | ESR2 3914/4885NR1H2 2419/4885USP2 2836/4885 |
| US-20110082294-A1 | NOVEL BICYCLIC COMPOUNDS | CCR2, CCR3, CCR1 | ESR2 490/4885NR1H2 194/4885USP2 4682/4885 |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | ESR2 1054/4885NR1H2 353/4885USP2 4037/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | ESR2 3253/4885NR1H2 3775/4885USP2 2469/4885 |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | ESR2 971/4885NR1H2 181/4885USP2 4741/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ESR2 2497/4885NR1H2 1741/4885USP2 4043/4885 |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | ESR2 654/4885NR1H2 135/4885USP2 4800/4885 |
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | ESR2 2790/4885NR1H2 3688/4885USP2 2402/4885 |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | ESR2 915/4885NR1H2 222/4885USP2 4729/4885 |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR1 | ESR2 1486/4885NR1H2 97/4885USP2 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.